Evidence map›Paper›PMID 42909918›Full record

ArticleTheranostics2026

DCTN2 inhibited cellular senescence through targeting TRIM21 mediated MST2 ubiquitination and activation in hepatocellular carcinoma.

Yanbo Wang, Yaomei He, Qin Yu, Ningrui Wang, Qiaoling Ruan, Haiyan Wang, Hanqing Zhao, Yonglin Zhang, Yang Ke, Caie Tang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yanbo WangDepartment of Geriatric Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266000, China.
Yaomei HeCenter for Life Sciences, Yunnan Key Laboratory of Cell Metabolism and Diseases, School of Life Sciences, Yunnan University, Kunming 650500, China.
Qin YuInstitute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, 637100, China.
Ningrui WangSchool of Pharmacy, Qingdao University, Qingdao 266021, China.
Qiaoling RuanYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Haiyan WangYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Hanqing ZhaoYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Yonglin ZhangYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Yang KeThe Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, China.
Caie TangYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Liqi LangYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Yuxia TangYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Lixia LiuYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Hao ZhangYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Shan YanYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Aimin WangDepartment of Geriatric Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266000, China.
Qiushuo ShenYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.
Ceshi ChenYunnan Key Laboratory of Breast Cancer Precision Medicine, Institute of Biomedical Engineering, Kunming Medical University, Kunming, 650500, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and inducing cellular senescence presents a promising therapeutic approach. However, the mechanisms underlying senescence in HCC pathogenesis remain unclear. This study investigated key genes involved in liver cancer senescence. Methods: Bioinformatic analyses of HCC datasets identified senescence-related genes, highlighting dynactin subunit 2 ( Results: DCTN2 was identified as a novel HCC senescence-associated gene, whose expression was transcriptionally upregulated by TP53 mutation. DCTN2 knockdown induced cellular senescence, thereby inhibiting HCC cell proliferation, migration, invasion and angiogenesis, whereas its overexpression exerted an opposite oncogenic effect. DCTN2 repressed cellular senescence via interaction with TRIM21, which decreased MST2 K63-linked polyubiquitination and ultimately attenuated the Hippo signaling pathway; Conclusions: Our findings revealed that DCTN2 suppresses cellular senescence by inhibiting the Hippo signaling pathway in HCC. Targeting the DCTN2/TRIM21/MST2 axis, along with TP53 mutation regulation, offers new therapeutic insights for HCC treatment.

Indexed as

Carcinoma, HepatocellularCellular SenescenceLiver NeoplasmsProtein Serine-Threonine KinasesRibonucleoproteinsAnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, NudeSignal TransductionSorafenibSS-A AntigenProtein Serine-Threonine KinasesRibonucleoproteinsSorafenibSS-A AntigenTP53 protein, humanTRIM21 ProteinTumor Suppressor Protein p53cellular senescencedynactin subunit 2hepatocellular carcinomaHippo signaling pathwaytripartite motif-containing 21

Identifiers

PMID42909918
PMCPMC13684392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.